MY205032A - Method for the management of dysmenorrhea and menstrual pain - Google Patents
Method for the management of dysmenorrhea and menstrual painInfo
- Publication number
- MY205032A MY205032A MYPI2019002318A MYPI2019002318A MY205032A MY 205032 A MY205032 A MY 205032A MY PI2019002318 A MYPI2019002318 A MY PI2019002318A MY PI2019002318 A MYPI2019002318 A MY PI2019002318A MY 205032 A MY205032 A MY 205032A
- Authority
- MY
- Malaysia
- Prior art keywords
- dysmenorrhea
- management
- estetrol
- compounds
- menstrual pain
- Prior art date
Links
- 208000005171 Dysmenorrhea Diseases 0.000 title abstract 4
- 206010013935 Dysmenorrhoea Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 abstract 1
- 229950009589 estetrol Drugs 0.000 abstract 1
- 230000001076 estrogenic effect Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000757 progestagenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/076104 WO2018065076A1 (fr) | 2016-10-28 | 2016-10-28 | Méthode de prise en charge de la dysménorrhée et des douleurs menstruelles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY205032A true MY205032A (en) | 2024-09-28 |
Family
ID=57209484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019002318A MY205032A (en) | 2016-10-28 | 2016-10-28 | Method for the management of dysmenorrhea and menstrual pain |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JP2018533542A (fr) |
| KR (1) | KR102780201B1 (fr) |
| AU (1) | AU2016425935B2 (fr) |
| CA (1) | CA3041016C (fr) |
| MY (1) | MY205032A (fr) |
| WO (1) | WO2018065076A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2383279A1 (fr) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Procédé de préparation d'estetrol |
| DK3701944T3 (da) | 2015-06-18 | 2022-03-14 | Estetra Srl | Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent |
| LT3310345T (lt) | 2015-06-18 | 2021-06-25 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CR20180042A (es) | 2015-06-18 | 2018-05-03 | Mithra Pharmaceuticals S A | Unidad de dosificación orodispersable que contiene un componente estetrol. |
| KR102712911B1 (ko) | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
| SG11202007163WA (en) | 2018-02-07 | 2020-08-28 | Estetra Sprl | Contraceptive composition with reduced cardiovascular effects |
| CN111989105B (zh) | 2018-04-19 | 2024-07-19 | 埃斯特拉私人有限责任公司 | 化合物以及它们在缓解绝经相关症状中的用途 |
| TWI801561B (zh) | 2018-04-19 | 2023-05-11 | 比利時商依思特拉私人有限責任公司 | 化合物及其用於緩解絕經相關症狀的用途 |
| HU231240B1 (hu) | 2019-09-03 | 2022-04-28 | Richter Gedeon Nyrt. | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| IT202000003964A1 (it) * | 2020-02-26 | 2021-08-26 | Umberto Cornelli | Composizione farmaceutica per l’uso nel trattamento di dismenorrea e/o sindrome premestruale |
| TWI893101B (zh) * | 2020-04-16 | 2025-08-11 | 比利時商埃斯特拉有限責任公司 | 具有降低之副作用之避孕組成物 |
| WO2022166599A1 (fr) * | 2021-02-02 | 2022-08-11 | 广州沪同有梧生物科技有限公司 | Nouvelle utilisation de pqq et de son dérivé |
| HUP2400151A1 (hu) | 2024-02-28 | 2025-09-28 | Richter Gedeon Nyrt | Ösztetrol-monohidrát kristályosítási eljárás |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4344405C2 (de) | 1993-12-24 | 1995-12-07 | Marika Dr Med Ehrlich | Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption |
| WO2012055840A1 (fr) * | 2010-10-28 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Composition et préparation pour le traitement de la dysménorrhée et de la douleur menstruelle et utilisation d'un agent hormonal et d'un sel de zinc pour le traitement de troubles menstruels |
| KR102712911B1 (ko) * | 2016-08-05 | 2024-10-04 | 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 | 월경통 및 생리통의 관리방법 |
-
2016
- 2016-10-28 CA CA3041016A patent/CA3041016C/fr active Active
- 2016-10-28 AU AU2016425935A patent/AU2016425935B2/en active Active
- 2016-10-28 KR KR1020197015235A patent/KR102780201B1/ko active Active
- 2016-10-28 JP JP2017529086A patent/JP2018533542A/ja active Pending
- 2016-10-28 MY MYPI2019002318A patent/MY205032A/en unknown
- 2016-10-28 WO PCT/EP2016/076104 patent/WO2018065076A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA3041016A1 (fr) | 2018-04-12 |
| KR20190076014A (ko) | 2019-07-01 |
| JP2018533542A (ja) | 2018-11-15 |
| CA3041016C (fr) | 2023-09-05 |
| KR102780201B1 (ko) | 2025-03-12 |
| AU2016425935B2 (en) | 2023-01-19 |
| WO2018065076A1 (fr) | 2018-04-12 |
| AU2016425935A1 (en) | 2019-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022011436A (es) | Metodo de manejo de dismenorrea y dolor menstrual. | |
| MY205032A (en) | Method for the management of dysmenorrhea and menstrual pain | |
| PH12019501812A1 (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| MY192848A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| NZ722326A (en) | Tricyclic compounds as anticancer agents | |
| MX2017016424A (es) | Compuestos para su uso en el tratamiento de trastornos neuromusculares. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| WO2015073587A3 (fr) | Complexes membrane synthétique- récepteur | |
| MX365294B (es) | Inhibidores de proteína cinasa dependiente de adn. | |
| AU2016261707A8 (en) | Use of cannabis to treat fibromyalgia, methods and compositions thereof | |
| PH12019502174A1 (en) | Modulators of pcsk9 expression | |
| NZ756936A (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
| MX2025006615A (es) | Metodos para alterar la composicion corporal | |
| MX2018004120A (es) | Composiciones fraguables con diversos tiempos de fraguado. | |
| PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
| PH12017500615B1 (en) | Ophthalmic composition comprising cyclosporine and trehalose | |
| MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
| MX2018003087A (es) | Metodo para influir en el tacto. | |
| MX2022015456A (es) | Composiciones de maca y metodos de uso. | |
| MX2019007041A (es) | Metodos y composiciones para tratar la enfermedad de parkinson. | |
| MX2016008821A (es) | Composiciones lacteas fermentadas coladas y aireadas. | |
| MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. | |
| MX2019009293A (es) | Compuestos, composiciones y usos de los mismos para la mejoria de trastornos oseos. | |
| MX2018006882A (es) | Composiciones farmacéuticas de estradiol insertadas por vía vaginal y métodos. | |
| ZA202005158B (en) | Performance enhancing additive for fuel composition, and method of use thereof |